16:53 , Jul 27, 2018 |  BC Week In Review  |  Company News

Gilead's Yescarta beats estimates

In its 2Q18 earnings, Gilead Sciences Inc. (NASDAQ:GILD) reported better than expected sales of CAR T cell therapy Yescarta axicabtagene ciloleucel. Sales for the drug were $68 million, beating the consensus estimate of $59.1 million...
01:11 , Jul 26, 2018 |  BC Extra  |  Company News

Gilead's Yescarta beats estimates

In its 2Q18 earnings released Wednesday, Gilead Sciences Inc. (NASDAQ:GILD) reported better than expected sales of CAR T cell therapy Yescarta axicabtagene ciloleucel. Sales for the drug were $68 million, beating the consensus estimate of...
18:15 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

EC approves Gilead's triple combo HIV therapy

Gilead Sciences Inc. (NASDAQ:GILD) said the European Commission approved an MAA for Biktarvy bictegravir/emtricitabine/tenofovir alafenamide to treat HIV-1 infection in adults without present or past evidence of viral resistance to the integrase class, emtricitabine or...
19:05 , May 4, 2018 |  BC Week In Review  |  Clinical News

CHMP recommends Gilead's triple combo HIV therapy

EMA’s CHMP recommended approval of Biktarvy bictegravir/emtricitabine/tenofovir alafenamide from Gilead Sciences Inc. (NASDAQ:GILD) to treat HIV-1 infection in adults without present or past evidence of viral resistance to the integrase class, emtricitabine or tenofovir. The...
18:18 , Apr 27, 2018 |  BC Extra  |  Company News

CHMP recommends Gilead's triple combo HIV therapy

EMA’s CHMP recommended approval of Biktarvy bictegravir/emtricitabine/tenofovir alafenamide from Gilead Sciences Inc. (NASDAQ:GILD) to treat HIV-1 infection in adults without present or past evidence of viral resistance to the integrase class, emtricitabine or tenofovir. The...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
19:58 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Gilead's switching to Biktarvy non-inferior in Phase III to treat HIV-1 in women

Gilead Sciences Inc. (NASDAQ:GILD) reported data from the open-label, international Phase III GS-US-380-1961 trial in 470 virologically suppressed adult women with HIV-1 infection showing that switching from either a boosted protease inhibitor or boosted Vitekta...
19:58 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Gilead reports additional Phase III data from HIV switching trial of Biktarvy

Gilead Sciences Inc. (NASDAQ:GILD) reported additional data from the Phase III GS-US-380-1844 trial in 563 virologically suppressed adults with HIV-1 infection showing that switching from either Tivicay dolutegravir plus abacavir/lamivudine or Triumeq dolutegravir/abacavir/lamivudine to once-daily...
16:23 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

FDA approves Gilead's triple combo HIV therapy

Gilead Sciences Inc. (NASDAQ:GILD) said FDA approved Biktarvy bictegravir/emtricitabine/tenofovir alafenamide to treat HIV-1 infection. Gilead told BioCentury it plans to launch the drug this week at a wholesale acquisition cost (WAC) of $2,945.65 for a...
01:13 , Feb 8, 2018 |  BC Extra  |  Company News

FDA approves Gilead's triple combo HIV therapy

Gilead Sciences Inc. (NASDAQ:GILD) said FDA approved Biktarvy bictegravir/emtricitabine/tenofovir alafenamide Wednesday to treat HIV-1 infection. Gilead told BioCentury it plans to launch the drug this week at a wholesale acquisition cost (WAC) of $2,945.65 for...